Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Capital Leases (2018 - 2022)

BioNexus Gene Lab's Capital Leases history spans 5 years, with the latest figure at $13021.0 for Q1 2022.

  • For Q1 2022, Capital Leases fell 55.02% year-over-year to $13021.0; the TTM value through Mar 2022 reached $13021.0, down 55.02%, while the annual FY2021 figure was $12803.0, 63.72% down from the prior year.
  • Capital Leases for Q1 2022 was $13021.0 at BioNexus Gene Lab, up from $12803.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $62935.0 in Q4 2018 and bottomed at $12803.0 in Q4 2021.
  • The 5-year median for Capital Leases is $38169.0 (2020), against an average of $35673.2.
  • The largest annual shift saw Capital Leases decreased 19.54% in 2020 before it plummeted 63.72% in 2021.
  • A 5-year view of Capital Leases shows it stood at $62935.0 in 2018, then decreased by 28.36% to $45086.0 in 2019, then dropped by 21.72% to $35292.0 in 2020, then tumbled by 63.72% to $12803.0 in 2021, then grew by 1.7% to $13021.0 in 2022.
  • Per Business Quant, the three most recent readings for BGLC's Capital Leases are $13021.0 (Q1 2022), $12803.0 (Q4 2021), and $18103.0 (Q3 2021).